Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
NCT ID: NCT05521022
Last Updated: 2024-04-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-09-01
Study Completion Date
2025-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
NCT05235269
Amyloidosis
COMPLETED
PHASE2
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
NCT05201911
Amyloidosis; Systemic
COMPLETED
PHASE1
Multiple Doses of AT-1501-A201 in Adults With ALS
NCT04322149
Amyotrophic Lateral Sclerosis
COMPLETED
PHASE2
Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects
NCT01559077
TTR-mediated Amyloidosis
COMPLETED
PHASE1
A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
NCT02797847
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Systemic amyloidosis is an incurable disease, and about 20% of patients with cardiac or advanced kidney involvement experience early deaths (\<1 year). Despite recent progress in proteasome inhibitors, chemotherapies, and immunotherapies that target plasma cells have greatly improved the prognosis of patients with systemic amyloidosis, median survival remains low at approximately five years.
AT-02 (INN: not yet available) is a full-length, humanized, recombinant immunoglobulin 1 (IgG1)-like glycoprotein monoclonal antibody (mAb) that is being developed to treat systemic amyloidosis.
This is a three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers (HV) and in subjects with systemic amyloidosis (SA) and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Part 1 is a double-blind, single-center, single-ascending dose escalation study in HV to assess the safety, tolerability, and PK of AT-02. Healthy volunteers between 18 to 56 years of will be enrolled in the Part 1 study.
Part 2 is an open-label, single-ascending dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, and PK of AT-02 and to identify a maximum tolerated dose (MTD). Subjects with SA over 18 years of age will be involved in the Part 2 study.
Part 3 is an open-label, multiple-ascending dose, dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, PK, PD, and clinical activity of multiple doses of AT-02. Subjects with SA ≥18 and ≤85 years of age will be involved in the Part 3 study.
AT-02 (INN: not yet available) is a full-length, humanized, recombinant immunoglobulin 1 (IgG1)-like glycoprotein monoclonal antibody (mAb) that is being developed to treat systemic amyloidosis.
This is a three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers (HV) and in subjects with systemic amyloidosis (SA) and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Part 1 is a double-blind, single-center, single-ascending dose escalation study in HV to assess the safety, tolerability, and PK of AT-02. Healthy volunteers between 18 to 56 years of will be enrolled in the Part 1 study.
Part 2 is an open-label, single-ascending dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, and PK of AT-02 and to identify a maximum tolerated dose (MTD). Subjects with SA over 18 years of age will be involved in the Part 2 study.
Part 3 is an open-label, multiple-ascending dose, dose escalation study in subjects with systemic amyloidosis to assess the safety, tolerability, PK, PD, and clinical activity of multiple doses of AT-02. Subjects with SA ≥18 and ≤85 years of age will be involved in the Part 3 study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Amyloidosis; Systemic
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Double blind (Part 1) Open Label (Part 2) Open Label (Part 3)
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1 AT-02
Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Drug: AT-02 Dosage: 30mg to 1000mg Dosage Form \& Route of Admin: Solution for IV Infusion
Group Type
EXPERIMENTAL
AT-02
Intervention Type
DRUG
AT-02 via IV infusion
Part 1 Placebo
Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Dosage Form \& Route of Admin: Normal Saline Solution for IV Infusion
Group Type
PLACEBO_COMPARATOR
AT-02 (Placebo)
Intervention Type
OTHER
Normal saline solution via IV infusion
Part 2 AT-02
Part 2 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: 300mg to 4000mg Frequency: Single Dose Dosage Form \& Route of Admin: Solution for IV Infusion
Group Type
EXPERIMENTAL
AT-02
Intervention Type
DRUG
AT-02 via IV infusion
Part 3 AT-02
Part 3 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: Dose levels will be determined by the SRC. The starting dose in Part 3 will be determined by the SRC based on all available safety, tolerability, PK, and PD data from all prior cohorts Frequency: Multiple Doses Dosage Form \& Route of Admin: Solution for IV Infusion
Group Type
EXPERIMENTAL
AT-02
Intervention Type
DRUG
AT-02 via IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AT-02
AT-02 via IV infusion
Intervention Type
DRUG
AT-02 (Placebo)
Normal saline solution via IV infusion
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Eligibility Criteria for Healthy Volunteers:
Healthy volunteers are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent
2. Male or female between \>18 and \<56 years of age.
3. Willing and able to comply with this protocol and informed consent and be available for the entire duration of the study.
4. Willing to abstain from alcohol and strenuous physical activity (i.e., strenuous or unaccustomed weightlifting, running, bicycling, etc.) from 48 hours prior to study treatment administration until discharge from the clinical unit and prior to each outpatient visit.
5. In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratory findings, and vital signs at Screening and Phase 1 unit Check-in.
6. Has body mass index (BMI) of 18 to 32 kg/m2, inclusive.
7. Women of childbearing potential (WOCBP)
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Postmenopausal females:
a) Postmenopausal females under the age of 55 years must have a documented serum follicle stimulating hormone (FSH) level \>40 mIU/mL to confirm menopause
9. Women of non-childbearing potential (WONCBP) and female participants with vasectomized male partners:
a) WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
10. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level.
5. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Eligibility Criteria for Part 2 Subjects with Systemic Amyloidosis
Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent
2. Male or female ≥18 and ≤80 years of age.
3. Mini Mental Status Exam (MMSE) score \>27 (subjects \>55 years of age only).
4. Has a confirmed diagnosis of AL, ATTR, or other form of systemic amyloidosis, based on any one of the following:
1. A histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry, mass spectrometry or identification of an amyloidogenic genetic variant;
2. Genetic screening with presence of amyloid-related pathology; or
3. Amyloid-specific imaging study (e.g., bone scintigraphy and echocardiogram/CMR consistent with ATTR cardiac amyloid).
5. Subjects with AL systemic amyloidosis must have achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) and within 12 months of Screening and may be receiving maintenance daratumumab.
6. Subjects with ATTR systemic amyloidosis may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Women of childbearing potential (WOCBP):
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:
1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
9. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants in same-sex relationships or in relationships with WONCBP, must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Eligibility Criteria for Part 3 Subjects with Systemic Amyloidosis
Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent.
2. Male or female ≥18 and ≤85 years of age.
3. Has a confirmed diagnosis of ATTR cardiomyopathy (ATTR-CM), AL, or other form of systemic amyloidosis
4. Imaging evidence of organ amyloid deposits.
5. For ATTR cardiomyopathy subjects, genetic testing confirming wild type ATTR or identification of an amyloidogenic genetic variant is required. If genetic testing has not been performed prior to screening, then the test may be ordered during screening
6. Subjects with ATTR cardiomyopathy may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Subjects with AL systemic amyloidosis may be receiving maintenance daratumumab and must have
1. Achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) within 12 months of Screening or
2. Achieved a partial hematologic response, is in stable condition (defined as \>6 months without clonal or amyloidotic organ progression), is not receiving plasma cell directed (PCD) therapy and is not expected to require PCD therapy for the duration of the study.
8. Women of childbearing potential (WOCBP):
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
9. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:
1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
10. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Healthy volunteers are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent
2. Male or female between \>18 and \<56 years of age.
3. Willing and able to comply with this protocol and informed consent and be available for the entire duration of the study.
4. Willing to abstain from alcohol and strenuous physical activity (i.e., strenuous or unaccustomed weightlifting, running, bicycling, etc.) from 48 hours prior to study treatment administration until discharge from the clinical unit and prior to each outpatient visit.
5. In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratory findings, and vital signs at Screening and Phase 1 unit Check-in.
6. Has body mass index (BMI) of 18 to 32 kg/m2, inclusive.
7. Women of childbearing potential (WOCBP)
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Postmenopausal females:
a) Postmenopausal females under the age of 55 years must have a documented serum follicle stimulating hormone (FSH) level \>40 mIU/mL to confirm menopause
9. Women of non-childbearing potential (WONCBP) and female participants with vasectomized male partners:
a) WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
10. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level.
5. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Eligibility Criteria for Part 2 Subjects with Systemic Amyloidosis
Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent
2. Male or female ≥18 and ≤80 years of age.
3. Mini Mental Status Exam (MMSE) score \>27 (subjects \>55 years of age only).
4. Has a confirmed diagnosis of AL, ATTR, or other form of systemic amyloidosis, based on any one of the following:
1. A histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry, mass spectrometry or identification of an amyloidogenic genetic variant;
2. Genetic screening with presence of amyloid-related pathology; or
3. Amyloid-specific imaging study (e.g., bone scintigraphy and echocardiogram/CMR consistent with ATTR cardiac amyloid).
5. Subjects with AL systemic amyloidosis must have achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) and within 12 months of Screening and may be receiving maintenance daratumumab.
6. Subjects with ATTR systemic amyloidosis may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Women of childbearing potential (WOCBP):
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:
1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
9. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants in same-sex relationships or in relationships with WONCBP, must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Eligibility Criteria for Part 3 Subjects with Systemic Amyloidosis
Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:
1. Understands the study procedures and can give signed informed consent.
2. Male or female ≥18 and ≤85 years of age.
3. Has a confirmed diagnosis of ATTR cardiomyopathy (ATTR-CM), AL, or other form of systemic amyloidosis
4. Imaging evidence of organ amyloid deposits.
5. For ATTR cardiomyopathy subjects, genetic testing confirming wild type ATTR or identification of an amyloidogenic genetic variant is required. If genetic testing has not been performed prior to screening, then the test may be ordered during screening
6. Subjects with ATTR cardiomyopathy may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Subjects with AL systemic amyloidosis may be receiving maintenance daratumumab and must have
1. Achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) within 12 months of Screening or
2. Achieved a partial hematologic response, is in stable condition (defined as \>6 months without clonal or amyloidotic organ progression), is not receiving plasma cell directed (PCD) therapy and is not expected to require PCD therapy for the duration of the study.
8. Women of childbearing potential (WOCBP):
1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
9. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:
1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
10. Male participants:
1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
4. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novotech (Australia) Pty Limited
INDUSTRY
Sponsor Role
collaborator
Attralus, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Midwest Heart and Vascular
Overland Park, Kansas, United States
Site Status
RECRUITING
Johns Hopkins
Baltimore, Maryland, United States
Site Status
RECRUITING
St. Luke's Hospital of Kansas City
Kansas City, Missouri, United States
Site Status
RECRUITING
Cleveland Clinic
Cleveland, Ohio, United States
Site Status
RECRUITING
OHSU (Oregon Health & Science University)
Portland, Oregon, United States
Site Status
RECRUITING
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Site Status
RECRUITING
Q-Pharm Pty Ltd
Herston, Queensland, Australia
Site Status
RECRUITING
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Site Status
RECRUITING
Flinders Medical Centre
Bedford Park, South Australia, Australia
Site Status
RECRUITING
Box Hill Hospital
Box Hill, Victoria, Australia
Site Status
RECRUITING
Royal Perth Hospital
Perth, Western Australia, Australia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Australia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Richard Friend
Role: primary
Dariusz Korczyk, Dr
Role: primary
Joseph Selvanayagam
Role: primary
Simon Gibbs
Role: primary
Graham Hillis
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AT02-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
NCT01148953
COMPLETED
PHASE1
Study of ATH434 in Participants with Multiple System Atrophy
NCT05109091
COMPLETED
PHASE2
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02579239
COMPLETED
PHASE1/PHASE2
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NCT02870634
COMPLETED
PHASE1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
NCT05517603
COMPLETED
PHASE1/PHASE2
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
NCT05053035
TERMINATED
PHASE2
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NCT01707264
COMPLETED
PHASE1/PHASE2
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810
RECRUITING
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
NCT06138743
RECRUITING
PHASE1/PHASE2
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
NCT00030381
TERMINATED
PHASE1
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
NCT05486481
WITHDRAWN
PHASE1/PHASE2
Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).
NCT02868580
COMPLETED
PHASE2
Study in Subjects With Light Chain (AL) Amyloidosis
NCT03154047
TERMINATED
PHASE2
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
NCT05199337
COMPLETED
PHASE1/PHASE2
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00748501
COMPLETED
PHASE2
Daratumumab for the Treatment of Patients With AL Amyloidosis
NCT02841033
COMPLETED
PHASE1/PHASE2
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
NCT00091260
COMPLETED
PHASE2
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren
NCT03796637
COMPLETED
PHASE2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
NCT01789242
COMPLETED
PHASE1
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898
COMPLETED
PHASE2
A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy
NCT05938023
TERMINATED
PHASE2
Study of SPG302 in Healthy Volunteers and ALS Participants
NCT05882695
COMPLETED
PHASE1
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866
ACTIVE_NOT_RECRUITING
PHASE2
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
NCT01753076
COMPLETED
PHASE2
Study of ATX-01 in Participants With DM1
NCT06300307
RECRUITING
PHASE1/PHASE2